- Telehealth Visits
Anuradha Banerjee, MD
Pediatric Hematology-OncologyAnuradha Banerjee, MD
Pediatric Hematology-Oncology- Telehealth Visits
On this page
About me
Dr. Anuradha Banerjee is a pediatrician with specialty training in pediatric hematology and oncology (blood cancers and other blood disorders). Her expertise encompasses brain tumors. She is also trained in pediatric palliative care.
Banerjee is an epidemiologist, a specialist who studies the causes and characteristics of disease. Her research focuses on the role of molecular predictors of clinical behavior in childhood leukemia and pneumococcal vaccination in children undergoing chemotherapy. She also works on clinical trials (studies to evaluate promising new treatments) with the Pediatric Brain Tumor Consortium, a multicenter research project of the National Cancer Institute.
Banerjee earned her medical degree and a master of public health degree in epidemiology at Tulane University. At UCSF, she completed a residency in pediatrics, a fellowship in pediatric hematology and oncology, and training in pediatric palliative care. She joined UCSF's neurological surgery department in 2001.
Education
Board Certification
- Pediatric Hematology-Oncology, American Board of Pediatrics
Fellowship
- Pediatric Hematology-Oncology, UCSF School of Medicine -GME
Residency
- Pediatrics, UCSF School of Medicine -GME
School
- MD, Tulane University School of Medicine
Academic Title
- Health Sciences Clinical Professor
Care Keywords
Services
- Pediatric Hematology-Oncology
Locations
Provider Research Listing
Browse clinical trials and publications by this provider
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.